The COVID-19 pandemics and the relevance of biosafety facilities for metagenomics surveillance, structured disease prevention and control

dc.creatorSouza, Thiago Moreno L.
dc.creatorMorel, Carlos Medicis
dc.date2020-12-15T19:41:34Z
dc.date2020-12-15T19:41:34Z
dc.date2020
dc.date.accessioned2023-09-26T20:08:22Z
dc.date.available2023-09-26T20:08:22Z
dc.identifierSOUZA, Thiago Moreno Lopes; MOREL, Carlos Medicis. The COVID-19 pandemics and the relevance of biosafety facilities for metagenomics surveillance, structured disease prevention and control. Biosafety and Health, p. 1-9, 29 Nov. 2020.
dc.identifier2590-0536
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/44921
dc.identifier10.1016/j.bsheal.2020.11.007
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8849478
dc.descriptionThe 2019 coronavirus disease (COVID-19) pandemic represents an enormous challenge to all countries, regardless of their development status. The manipulation of its etiologic agent SARS-CoV-2 requires a biosafety containment level 3 laboratories (BSL-3) to understand virus biology and in vivo pathogenesis as well as the translation of new knowledge into the preclinical development of vaccines and antivirals. As such, BSL-3 facilities should be considered an integral part of any public health response to emerging infectious disease prevention, control and management. Differently from BSL2, BSL-3 units vary considerably along the range from industrialized to the least developed countries. Innovative Developing Countries (IDCs) such as Brazil, which excelled at controlling the 2015-2017 Zika epidemic, had to face a serious flaw in its disease control and prevention structure: the scarcity and uneven geographic distribution of its BSL-3 facilities, including those for preclinical animal experimentation.
dc.formatapplication/pdf
dc.languageeng
dc.publisherElsevier
dc.relationhttps://www.arca.fiocruz.br/handle/icict/52484
dc.rightsopen access
dc.subjectSARS-CoV-2
dc.subjectCOVID-19
dc.subjectInstalações de biossegurança
dc.subjectPaíses em desenvolvimento de inovação (IDCs)
dc.subjectVigilância metagenômica
dc.subjectSARS-CoV-2
dc.subjectCOVID-19
dc.subjectBiosafety facilities
dc.subjectInnovative Developing Countries (IDCs)
dc.subjectMetagenomics surveillance
dc.titleThe COVID-19 pandemics and the relevance of biosafety facilities for metagenomics surveillance, structured disease prevention and control
dc.typePreprint


Este ítem pertenece a la siguiente institución